FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3113016602> ?p ?o ?g. }

• W3113016602 abstract "Abstract Background SARS-CoV-2 has caused over 36,000,000 cases and 1,000,000 deaths globally. Comprehensive assessment of the multifaceted anti-viral antibody response is critical for diagnosis, differentiation of severe disease, and characterization of long-term immunity. Initial observations suggest that severe disease is associated with higher antibody levels and greater B cell/plasmablast responses. A multi-antigen immunoassay to define the complex serological landscape and clinical associations is essential. Methods We developed a multiplex immunoassay and evaluated serum/plasma from adults with RT-PCR-confirmed SARS-CoV-2 infections during acute illness (N=52) and convalescence (N=69); and pre-pandemic (N=106) and post-pandemic (N=137) healthy adults. We measured IgA, IgG, and/or IgM against SARS-CoV-2 Nucleocapsid (N), Spike domain 1 (S1), receptor binding domain (S1-RBD) and S1-N-terminal domain (S1-NTD). Results To diagnose infection, the combined [IgA+IgG+IgM] or IgG for N, S1, and S1-RBD yielded AUC values −0.90 by ROC curves. From days 6-30 post-symptom onset, the levels of antigen-specific IgG, IgA or [IgA+IgG+IgM] were higher in patients with severe/critical compared to mild/moderate infections. Consistent with excessive concentrations of antibodies, a strong prozone effect was observed in sera from severe/critical patients. Notably, mild/moderate patients displayed a slower rise and lower peak in anti-N and anti-S1 IgG levels compared to severe/critical patients, but anti-RBD IgG and neutralization responses reached similar levels at 2-4 months. Conclusion This SARS-CoV-2 multiplex immunoassay measures the magnitude, complexity and kinetics of the antibody response against multiple viral antigens. The IgG and combined-isotype SARS-CoV-2 multiplex assay is highly diagnostic of acute and convalescent disease and may prognosticate severity early in illness. One Sentence Summary In contrast to patients with moderate infections, those with severe COVID-19 develop prominent, early antibody responses to S1 and N proteins." @default.
• W3113016602 created "2020-12-21" @default.
• W3113016602 creator A5002616480 @default.
• W3113016602 creator A5006055711 @default.
• W3113016602 creator A5006996562 @default.
• W3113016602 creator A5007443306 @default.
• W3113016602 creator A5015890102 @default.
• W3113016602 creator A5019586284 @default.
• W3113016602 creator A5023302154 @default.
• W3113016602 creator A5027533102 @default.
• W3113016602 creator A5031646130 @default.
• W3113016602 creator A5037956669 @default.
• W3113016602 creator A5043889746 @default.
• W3113016602 creator A5045495959 @default.
• W3113016602 creator A5046764809 @default.
• W3113016602 creator A5050971423 @default.
• W3113016602 creator A5052160637 @default.
• W3113016602 creator A5053912375 @default.
• W3113016602 creator A5055504564 @default.
• W3113016602 creator A5056206673 @default.
• W3113016602 creator A5058186904 @default.
• W3113016602 creator A5060507732 @default.
• W3113016602 creator A5061634030 @default.
• W3113016602 creator A5072098880 @default.
• W3113016602 creator A5072618297 @default.
• W3113016602 creator A5074507227 @default.
• W3113016602 creator A5080889629 @default.
• W3113016602 creator A5086057467 @default.
• W3113016602 creator A5087588959 @default.
• W3113016602 date "2020-12-06" @default.
• W3113016602 modified "2023-10-07" @default.
• W3113016602 title "Elevated SARS-CoV-2 Antibodies Distinguish Severe Disease in Early COVID-19 Infection" @default.
• W3113016602 cites W2005524843 @default.
• W3113016602 cites W2037286123 @default.
• W3113016602 cites W2047314106 @default.
• W3113016602 cites W2069610017 @default.
• W3113016602 cites W2965090569 @default.
• W3113016602 cites W3008962515 @default.
• W3113016602 cites W3009219040 @default.
• W3113016602 cites W3014656992 @default.
• W3113016602 cites W3017186084 @default.
• W3113016602 cites W3021590963 @default.
• W3113016602 cites W3031369346 @default.
• W3113016602 cites W3033022675 @default.
• W3113016602 cites W3033450058 @default.
• W3113016602 cites W3035749934 @default.
• W3113016602 cites W3036386821 @default.
• W3113016602 cites W3038536401 @default.
• W3113016602 cites W3040899749 @default.
• W3113016602 cites W3041613160 @default.
• W3113016602 cites W3042587425 @default.
• W3113016602 cites W3044482768 @default.
• W3113016602 cites W3044660350 @default.
• W3113016602 cites W3047996214 @default.
• W3113016602 cites W3048274045 @default.
• W3113016602 cites W3049009497 @default.
• W3113016602 cites W3049048202 @default.
• W3113016602 cites W3083337806 @default.
• W3113016602 cites W3091861357 @default.
• W3113016602 cites W3092050672 @default.
• W3113016602 cites W3092610091 @default.
• W3113016602 cites W3093083319 @default.
• W3113016602 cites W4246504300 @default.
• W3113016602 doi "https://doi.org/10.1101/2020.12.04.410589" @default.
• W3113016602 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7724666" @default.
• W3113016602 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33299998" @default.
• W3113016602 hasPublicationYear "2020" @default.
• W3113016602 type Work @default.
• W3113016602 sameAs 3113016602 @default.
• W3113016602 citedByCount "4" @default.
• W3113016602 countsByYear W31130166022021 @default.
• W3113016602 countsByYear W31130166022022 @default.
• W3113016602 crossrefType "posted-content" @default.
• W3113016602 hasAuthorship W3113016602A5002616480 @default.
• W3113016602 hasAuthorship W3113016602A5006055711 @default.
• W3113016602 hasAuthorship W3113016602A5006996562 @default.
• W3113016602 hasAuthorship W3113016602A5007443306 @default.
• W3113016602 hasAuthorship W3113016602A5015890102 @default.
• W3113016602 hasAuthorship W3113016602A5019586284 @default.
• W3113016602 hasAuthorship W3113016602A5023302154 @default.
• W3113016602 hasAuthorship W3113016602A5027533102 @default.
• W3113016602 hasAuthorship W3113016602A5031646130 @default.
• W3113016602 hasAuthorship W3113016602A5037956669 @default.
• W3113016602 hasAuthorship W3113016602A5043889746 @default.
• W3113016602 hasAuthorship W3113016602A5045495959 @default.
• W3113016602 hasAuthorship W3113016602A5046764809 @default.
• W3113016602 hasAuthorship W3113016602A5050971423 @default.
• W3113016602 hasAuthorship W3113016602A5052160637 @default.
• W3113016602 hasAuthorship W3113016602A5053912375 @default.
• W3113016602 hasAuthorship W3113016602A5055504564 @default.
• W3113016602 hasAuthorship W3113016602A5056206673 @default.
• W3113016602 hasAuthorship W3113016602A5058186904 @default.
• W3113016602 hasAuthorship W3113016602A5060507732 @default.
• W3113016602 hasAuthorship W3113016602A5061634030 @default.
• W3113016602 hasAuthorship W3113016602A5072098880 @default.
• W3113016602 hasAuthorship W3113016602A5072618297 @default.
• W3113016602 hasAuthorship W3113016602A5074507227 @default.
• W3113016602 hasAuthorship W3113016602A5080889629 @default.
• W3113016602 hasAuthorship W3113016602A5086057467 @default.
• W3113016602 hasAuthorship W3113016602A5087588959 @default.

• next